Phase 2 Study of Enzalutamide and GnRH Agonist Before, During and After Radiation Therapy in Treatment of Patients With High-risk Localized Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 May 2018
At a glance
- Drugs Enzalutamide (Primary) ; Leuprorelin
- Indications Prostate cancer
- Focus Adverse reactions
- 09 May 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Mar 2014 Planned End Date changed from 1 Apr 2017 to 1 Apr 2019 as reported by ClinicalTrial.gov record.
- 01 Mar 2014 New trial record